Based in Lexington, Kentucky, LevTech will be combined with ATMI’s existing LifeSciences business focused on single-use bioprocess containers and processes for the biopharmaceutical industry. Doug Neugold, CEO of
If the non-radiolabeled TM601 receives FDA approval for malignant glioma, it will entitle TransMolecular to exclusive marketing rights for the compound for the treatment of malignant glioma for
Through the collaboration, Centocor will support the discovery research and preclinical development by Catalyst of Alterase drug candidates against two targets, one of which is in inflammatory disease,
This one-year extension of the research phase of the agreement will result in NicOx receiving E3 million in research funding in March 2008. Under the terms of the
According to Specialty Blades, the acquisition of Popper makes the combined company the leading contract manufacturer of cutting and piercing devices for the medical device industry. The combined
The company said that preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development. EVT 302 was investigated in
The company expects to record after-tax charges of approximately $240 million in connection with the transaction. Jim Tobin, president and CEO of Boston Scientific, said: “We have now
Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical R&D efforts for TT-033. Pfizer will fund all aspects of
Safety needles are products used to access patients’ blood during the vast majority of chronic dialysis therapy treatments. MasterGuard is claimed to be the leading product in this
Orphan drug designation would entitle Fovea to exclusive marketing rights in the European countries for 10 years should Fovea be the first company to receive marketing approval for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.